Lecanemab Seeks Out Amyloid-Beta Protofibrils and Plaques
A short placeholder on antibody targeting of amyloid.
- Aβ protofibril: Target (Illustrative binding target)
- Humanized IgG1: Antibody type (Illustrative isotype note)
- IV infusion: Route (Illustrative dosing note)
- Biweekly: Frequency (Illustrative schedule note)
Antibody recognition of amyloid species
Placeholder: antibody scans and recognizes amyloid targets.
Antibody Coating Marks Plaques for Immune Recognition
A short placeholder on plaque opsonization dynamics.
- Surface coat: Opsonization (Illustrative coating stat)
- FcγR binding: Fc engagement (Illustrative receptor note)
- Dense: Coverage (Illustrative density note)
- Clearance flag: Signal (Illustrative signal note)
Opsonization marks plaques for clearance
Placeholder: bound antibodies flag plaques for microglia.
Microglia Engulf Antibody-Tagged Amyloid Deposits
A short placeholder on microglial phagocytosis.
- Phagocytosis: Mechanism (Illustrative clearance mechanism)
- Microglia: Cell type (Illustrative effector cell)
- Fc receptor: Trigger (Illustrative trigger note)
- Plaque shrinkage: Outcome (Illustrative outcome note)
Microglial engulfment of opsonized plaques
Placeholder: microglia consume tagged plaques over time.
Cumulative Plaque Burden Falls Across the Infusion Course
A short placeholder on burden reduction over months.
- 0–18 months: Timeline (Illustrative treatment window)
- Centiloid: PET metric (Illustrative imaging metric)
- Declining: Trend (Illustrative burden trend)
- Serial PET: Monitoring (Illustrative monitoring note)
Burden decline over the treatment course
Placeholder: PET burden trends down with more infusions.
Relating Amyloid Clearance to Clinical Outcome Trends
A short placeholder on clearance-outcome correlation.
- CDR-SB: Endpoint (Illustrative outcome measure)
- Modest: Correlation (Illustrative correlation note)
- Monitored: ARIA risk (Illustrative safety note)
- Slowed decline: Benefit (Illustrative benefit note)
Clearance versus cognitive outcome trend
Placeholder: greater clearance loosely tracks slower decline.
Placeholder highlight: illustrative only, not clinical guidance.